Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has proved helpful hard but unsuccessfully to develop an one off therapy, variously called Pro 140, leronlimab, as well as Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be used is an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV have been closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of the last several shares of mine. The 1st CytoDyn article of mine, “CytoDyn: What to be able to Do When It’s Too Good In order to Be True?”, set out all of the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such an extremely marketing picture in the Uptick Newswire employment interview that I came away with an inadequate viewpoint of the company.

Irony of irony, my bad impression of the business has grown steadily, although the disappointment has not been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > 6 bagger at the moment still disappoints? Therein is the story; permit me to explain.

CytoDyn acquired its much-storied treatment (which I shall refer to as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the treatment as well as reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti viral activity of HIV infected subjects. Today’s payment of $3.5 zillion transfers ownership of this know-how as well as linked intellectual property coming from Progenics to CytoDyn, and also roughly twenty five million mg of majority drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 million) and the very first brand new drug program endorsement ($5 million), and even royalty payments of 5 percent of net sales upon commercialization.

Since that time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous therapies and multiple indications, it’s this individual remedy in addition to a “broad pipeline of indications” since it places it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a likely beneficial therapy of dozens of indications.

The opening banner of its on the website of its (below) shows an energetic organization with diverse interests albeit centered on leronlimab, several disease types, multiple publications and multiple delivering presentations.

Could all of it be smoke cigarettes and mirrors? That’s a question I’ve been asking myself through the really start of the interest of mine in this particular organization. Judging by way of the multiples of a huge number of various commentary on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am far from alone in this particular question.

CytoDyn is a traditional battleground, or possibly some may say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *